Gene Editing For Sickle Cell Disease

NCT06506461 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: Plerixafor
DRUG: Busulfan
BIOLOGICAL: Gene-modified CD34+ cells
DRUG: Motixafortide

Sponsor

St. Jude Children's Research Hospital

Collaborators

[object Object]